Pancreatic fat content may increase the risk of imaging progression in low-risk branch duct intraductal papillary mucinous neoplasm.
Adipose Tissue
/ diagnostic imaging
Aged
Disease Progression
Female
Humans
Male
Middle Aged
Pancreas
/ diagnostic imaging
Pancreatic Ducts
/ diagnostic imaging
Pancreatic Intraductal Neoplasms
/ diagnostic imaging
Pancreatic Neoplasms
/ diagnostic imaging
Registries
Retrospective Studies
Risk Factors
Spleen
/ diagnostic imaging
Tomography, X-Ray Computed
computed tomography attenuation index
imaging progression
initial cyst size
pancreatic fat content
pancreatic intraductal neoplasms
pancreatic intraductal papillary mucinous neoplasms
Journal
Journal of digestive diseases
ISSN: 1751-2980
Titre abrégé: J Dig Dis
Pays: Australia
ID NLM: 101302699
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
12
03
2019
revised:
22
04
2019
accepted:
16
07
2019
pubmed:
20
7
2019
medline:
17
3
2020
entrez:
20
7
2019
Statut:
ppublish
Résumé
To identify risk factors of imaging progression (increase in cyst size or main pancreatic duct size, or a new mural nodule) in low-risk branch duct intraductal papillary mucinous neoplasm (BD-IPMN), including obesity-related factors such as pancreatic fat content. Our hospital databases were searched for patients who had completed health checkup, including upper abdominal magnetic resonance imaging (MRI) over 48 months (August 2012 to July 2016). Individuals with BD-IPMN without worrisome features and high-risk stigmata who underwent surveillance with at least one follow-up MRI, irrespective of the follow-up period, were included. Pancreatic computed tomography attenuation indexes were defined as the difference between the pancreas and spleen attenuation (P - S) and the pancreas to spleen attenuation ratio (P/S). Among 75 patients diagnosed as having low-risk BD-IPMN, during a median follow-up of 36 months, 11 (15%) had imaging progression in cyst size, including two with worrisome features. A multivariate logistic analysis showed that the initial cyst size and both indexes (P - S, or P/S) were significantly associated with imaging progression in IPMN, respectively (Model 1: odds ratio [OR] 1.188, 95% confidence interval [CI] 1.060-1.331, P = 0.003; OR 0.871, 95% CI 0.776-0.977, P = 0.019; Model 2: OR 1.186, 95% CI 1.064-1.322, P = 0.002; OR 0.002, 95% CI 0.000-0.970, P = 0.049). Pancreatic fat content and initial cyst size were significantly associated with imaging progression in low-risk BD-IPMN. Revisions of international consensus Fukuoka guidelines might be customized based on initial cyst size and pancreatic fat content.
Identifiants
pubmed: 31322828
doi: 10.1111/1751-2980.12801
doi:
Types de publication
Evaluation Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
557-562Subventions
Organisme : The authors received no specific funding for this work.
Informations de copyright
© 2019 Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd.
Références
Hruban RH, Maitra A, Kern SE, Goggins M. Precursors to pancreatic cancer. Gastroenterol Clin North Am. 2007;36(4):831-849.
Tanaka M, Fernández-Del Castillo C, Kamisawa T, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology. 2017;17(5):738-753.
Fong ZV, Ferrone CR, Lillemoe KD, Fernández-Del Castillo C. Intraductal papillary mucinous neoplasm of the pancreas: current state of the art and ongoing controversies. Ann Surg. 2016;263(5):908-917.
Anand N, Sampath K, Wu BU. Cyst features and risk of malignancy in intraductal papillary mucinous neoplasms of the pancreas: a meta-analysis. Clin Gastroenterol Hepatol. 2013;11(8):913-921.
Sultana A, Jackson R, Tim G, et al. What is the best way to identify malignant transformation within pancreatic IPMN: a systematic review and meta-analyses. Clin Transl Gastroenterol. 2015;6(12):e130. https://doi.org/10.1038/ctg.2015.60.
Kang MJ, Jang JY, Kim SJ, et al. Cyst growth rate predicts malignancy in patients with branch duct intraductal papillary mucinous neoplasms. Clin Gastroenterol Hepatol. 2011;9(1):87-93.
Ohno E, Hirooka Y, Kawashima H, et al. Natural history of pancreatic cystic lesions: a multicenter prospective observational study for evaluating the risk of pancreatic cancer. J Gastroenterol Hepatol. 2018;33(1):320-328.
Morales-Oyavide V, Mino-Kenudson M, Ferrone CR, et al. Diabetes mellitus in intraductal papillary mucinous neoplasm of the pancreas is associated with high-grade dysplasia and invasive carcinoma. Pancreatology. 2017;17(6):920-926.
Chang YT, Tien YW, Jeng YM, et al. Overweight increases the risk of malignancy inpatients with pancreatic mucinous cystic neoplasms. Medicine (Baltimore). 2015;94(20):e797. https://doi.org/10.1097/MD.0000000000000797.
Crippa S, Bassi C, Salvia R, et al. Low progression of intraductal papillary mucinous neoplasms with disturbing features and high-risk stigmata undergoing non-operative management: a mid-term follow-up analysis. Gut. 2017;66(3):495-506.
Wang CY, Ou HY, Chen MF, Chang TC, Chang CJ. Enigmatic ectopic fat: prevalence of nonalcoholic fatty pancreas disease and its associated factors in a Chinese population. J Am Heart Assoc. 2014;3(1):e000297. https://doi.org/10.1161/JAHA.113.000297.
Zhou J, Li ML, Zhang DD, et al. The correlation between pancreatic steatosis and metabolic syndrome in a Chinese population. Pancreatology. 2016;16(4):578-583.
Hori M, Takahashi M, Hiraoka N, et al. Association of pancreatic fatty infiltration with pancreatic ductal adenocarcinoma. Clin Transl Gastroenterol. 2014;5(3):e53. https://doi.org/10.1038/ctg.2014.5.
Rebours V, Gaujoux S, d'Assignies G, et al. Obesity and fatty pancreatic infiltration are risk factors for pancreatic precancerous lesions (PanIN). Clin Cancer Res. 2015;21(15):3522-3528.
Singh RG, Yoon HD, Wu LM, Lu J, Plank LD, Petrov MS. Ectopic fat accumulation in the pancreas and its clinical relevance: a systematic review, meta-analysis, and meta-regression. Metabolism. 2017;69:1-13.
Gausman V, Kandel P, Van Riet PA, et al. Predictors of progression among low-risk intraductal papillary mucinous neoplasms in a multicenter surveillance cohort. Pancreas. 2018;47(4):471-476.
Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014;371(11):1039-1049.
Kashiwagi K, Seino T, Fukuhara S, et al. Pancreatic fat content detected by computed tomography and its significant relationship with intraductal papillary mucinous neoplasm. Pancreas. 2018;47(9):1087-1092.
Girometti R, Pravisani R, Intini SG, et al. Evolution of incidental branch-duct intraductal papillary mucinous neoplasms of the pancreas: a study with magnetic resonance imaging cholangiopancreatography. World J Gastoenterol. 2016;22(43):9562-9570.
Kim SY, Kim H, Cho JY, et al. Qualitative assessment of pancreatic fat by using unenhanced CT: pathologic correlation and clinical implications. Radiology. 2014;271(1):104-112.
Yamagishi K, Iso H. The criteria for metabolic syndrome and the national health screening and education system in Japan. Epidemiol Health. 2017;39:e2017003. https://doi.org/10.4178/epih.e2017003.
Farrell GC, Chitturi S, Lau GK, Sollano JD. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J Gastroenterol Hepatol. 2007;22(6):775-777.
Crippa S, Capurso G, Cammà C, Fave GD, Fernández-Del Castillo C, Falconi M. Risk of pancreatic malignancy and mortality in branch-duct IPMN undergoing surveillance: a systematic review and meta-analysis. Dig Liver Dis. 2016;48(5):473-479.
Han Y, Lee H, Kang JS, et al. Progression of pancreatic branch duct intraductal papillary mucinous neoplasm associates with cyst size. Gastroenterology. 2018;154(3):576-584.
Fukuda Y, Yamada D, Eguchi H, et al. CT density in the pancreas is a promising imaging predictor for pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2017;24(9):2762-2769.